iTeos Therapeutics Appoints New CMO, Dr. Khan
| Field | Detail |
|---|---|
| Company | Iteos Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, personnel
TL;DR
New CMO at iTeos! Dr. Khan takes over from Dr. Quéva, starting June 3rd.
AI Summary
On June 1, 2025, iTeos Therapeutics, Inc. reported the departure of Dr. Christophe Quéva as Chief Medical Officer. The company also announced the appointment of Dr. Mohamed Z. Khan as the new Chief Medical Officer, effective June 3, 2025. Dr. Khan will receive an annual base salary of $450,000 and is eligible for equity awards.
Why It Matters
A change in Chief Medical Officer can signal shifts in clinical strategy or development focus for a biotechnology company.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can introduce uncertainty regarding the company's strategic direction and drug development pipeline.
Key Numbers
- $450,000 — Annual Base Salary (For new Chief Medical Officer, Dr. Mohamed Z. Khan.)
Key Players & Entities
- iTeos Therapeutics, Inc. (company) — Registrant
- Dr. Christophe Quéva (person) — Departing Chief Medical Officer
- Dr. Mohamed Z. Khan (person) — Appointed Chief Medical Officer
- $450,000 (dollar_amount) — Dr. Khan's annual base salary
FAQ
What is the effective date of Dr. Mohamed Z. Khan's appointment as Chief Medical Officer?
Dr. Mohamed Z. Khan's appointment is effective June 3, 2025.
Who is the departing Chief Medical Officer?
Dr. Christophe Quéva is the departing Chief Medical Officer.
What is Dr. Khan's starting annual base salary?
Dr. Khan's annual base salary is $450,000.
What is the company's principal executive office address?
The company's principal executive office is located at 321 Arsenal Street, Watertown, Massachusetts 02472.
What is the SIC code for iTeos Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for iTeos Therapeutics, Inc. is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 5, 2025 by Dr. Christophe Quéva regarding iTeos Therapeutics, Inc..